On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Exosomes as a New Class of Cell-Free Therapeutics and Diagnostics
Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers (nm). Exosomes are formed by the invagination of the cell membrane. This invagination and subsequent budding result in the formation of early endosomes. These early endosomes then mature into late endosomes, which are also called multivesicular bodies (MVBs). Finally, these MVBs migrate and fuse with the plasma membrane to release exosomes outside the cell. [Read more…]
MSCs as “Therapeutic Workhouses” in the Era of Regenerative Medicine
MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
An Introduction to Exosome Therapy And Its Costs
Are you curious about how exosomes relate to conversations about stem cells? Maybe you’ve heard of exosome therapy and its regenerative capabilities.
But what exactly is exosome therapy and what are its benefits? Keep reading for an introduction to exosomes so you can better understand how this therapy is advancing the field of modern medicine as we know it. [Read more…]
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects
CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the United States. This procedure was performed by Dr. Justin Newman at Orthopedic Centers of Colorado. [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 341
- Next Page »